Cardiovascular Drugs Market 2020 Estimated Size, Industry Share, Future Predications, Global Analysis, Competitive Landscape, And Regional Forecast To 2026

Some of the common cardiovascular diseases include hypertensive heart disease, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease. Major problems associated with hypertensive heart disease include angina, hypertrophy, and heart failure. These problems are caused due to high blood pressure in the heart’s arteries and muscles, which causes narrowing of arteries and thickening and enlargement of heart. The global cardiovascular drug market is primarily driven by rising prevalence of heart diseases coupled with rising geriatric population and lifestyle related diseases. Moreover, to cater increasing incidences of cardiovascular diseases, drugs for treatment and prevention for these diseases is required. Rising number of diabetic patients is also expected to be another factor that is expected to drive growth of the global cardiovascular drugs market. For instance, according to the American Diabetes Association, in 2015, 30.3 million Americans had diabetes, which is 9.4% of the total U.S. population.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1167

Manufacturers in the market are focusing on mergers and acquisitions and new product launches, which is positively affecting the market growth. However, stringent drug approval process and side effects of some cardiovascular drugs are the factors that are expected to hamper growth of the global cardiovascular drugs market. Moreover, patent expiry of various drugs is also expected to hamper revenue growth of the global cardiovascular drugs market.

According to American Heart Association (AHA), in 2013, cardiovascular diseases accounted for over 17.3 million deaths globally, representing 31% of all global deaths. The global number is expected to rise to 23.6 million by 2030. In 2010, the global burden of cardiovascular diseases was US$ 863 billion, and it is expected to rise to US$ 1044 billion by 2030. Around 2,200 U.S. citizens die due to cardiovascular diseases, everyday, which is one death in every 40 seconds. Moreover, coronary heart disease accounts for (45.1%) of the total cardiovascular disease, followed by stroke (16.5%), high blood pressure (9.1%), heart failure (8.5%), diseases related to arteries (3.2%), and other cardiovascular diseases in the U.S.

Quick Buy – Cardiovascular Drugs Market Research Report: https://bit.ly/3bQESZj

Global Cardiovascular Drugs Market Taxonomy

On the basis of drug class, the global cardiovascular drugs market is segmented into:

• Anti-hypertensive
• Anti-hyperlipidemics
• Anti-coagulants
• Anti-arrhythmic
• Anti-fibrinolytic
• Others (Anti-anginal Drugs, Cardiac Glycosides, and Anti-ischemic Drugs)

On the basis of distribution channels, the global cardiovascular drugs market is segmented into:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Increasing R&D activities to launch new products is expected to support growth of the cardiovascular drugs market

Regional segmentation of the cardiovascular drugs market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Africa, and Middle East. Global cardiovascular drugs market is oligopolistic in nature with few players holding majority of the share. Various strategies are adopted by key market players such as new product launches, and partnerships, in order to retain their market position. For instance, in December 2017, Medicure Inc., a Canada-based pharmaceutical company through its subsidiary Medicure International Inc., acquired exclusive license for 7 years to market and sell cardiovascular drug for the treatment of primary hyperlipidemia or mixed dyslipidemia in the U.S and its territories. In October 2017, Sun Pharmaceutical Industries’ subsidiary in the U.S received approval from the U.S Food and Drug Administration (FDA) to sell generic version of its Coreg CR. Coreg CR is used to treat various heart conditions including high blood pressure and heart failure. In August 2017, Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals entered into partnership to develop next generation products for the treatment of cardiovascular diseases and heart failure.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1167

Some of the major players operating in the global cardiovascular drugs market include Pfizer Inc., Bayer AG., Novartis AG., Merck and Co. Inc., AstraZeneca Plc, Bristol Myers Squibb Company, Abbott Laboratories, Sun Pharma Industries, Gilead Sciences Inc., Otsuka Holdings Co., Ltd. Takeda Pharmaceutical Company Ltd, Eli Lilly and Company, and Johnson & Johnson.

Table of Content

Global Cardiovascular Drugs Market Research Report
Section 1: Global Cardiovascular Drugs Industry Overview
Section 2: Global Economic Impact on Cardiovascular Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Cardiovascular Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Cardiovascular Drugs Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837